Alterations of basic blood parameters in Iraqi COVID-19 patients with hyperglycaemia and acute kidney injury
DOI:
https://doi.org/10.60988/p.v37i2S.193Keywords:
COVID-19; diabetes; acute kidney injury; D-dimer; ureaAbstract
Emerging evidence indicates that coronavirus disease 2019 (COVID-19) can exert direct effects on the kidneys, leading to acute kidney injury (AKI). This is particularly concerning for individuals with diabetic nephropathy, who may already exhibit compromised renal function. The pathophysiology of COVID-19-related AKI may involve mechanisms such as a direct viral invasion of renal cells, systemic inflammation, and microvascular damage. Our study has included a total of 250 patients with confirmed COVID-19 that were treated between February and April 2022 in designated COVID-19 centres throughout the Babil Province (Iraq). Clinical and laboratory data were retrospectively obtained from the patients’ medical records. Across all COVID-19 severity categories, our study has observed notable elevations in blood markers, including urea, creatinine, D-dimer, and blood glucose levels. Moreover, male patients exhibited significantly higher levels of urea, creatinine, D-dimer, C-reactive protein, and blood glucose compared to female patients (p<0.05). Our study’s findings suggest that diabetes mellitus and AKI can both be associated with heightened systemic inflammation and greater disease severity, and could be key predictors of adverse COVID-19 outcomes.
References
1. Allenbach Y., Saadoun D., Maalouf G., Vieira M., Hellio A., Boddaert J., et al. Development of a multivariate prediction model of intensive care unit transfer or death: a French prospective cohort study of hospitalized COVID-19 patients. PLoS One 15(10), e0240711, 2020. DOI: 10.1371/journal.pone.0240711
2. Arabi Y.M., Murthy S., Webb S. COVID-19: a novel coronavirus and a novel challenge for critical care. Intensive Care Med. 46(5), 833–836, 2020. DOI: 10.1007/s00134-020-05955-1
3. Bode B., Garrett V., Messler J., McFarland R., Crowe J., Booth R., et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J. Diabetes Sci. Technol. 14(4), 813–821, 2020. DOI: 10.1177/1932296820924469
4. Betjes M.G. Immune cell dysfunction and inflammation in end-stage renal disease. Nat. Rev. Nephrol. 9(5), 255–265, 2013. DOI: 10.1038/nrneph.2013.44
5. Bonetti G., Manelli F., Bettinardi A., Borrelli G., Fiordalisi G., Marino A., et al. Urinalysis parameters for predicting severity in coronavirus disease 2019 (COVID-19). Clin. Chem. Lab. Med. 58(9), e163–e165, 2020. DOI: 10.1515/cclm-2020-0576
6. Keivani Boroujeni E., Kellner S.J., Pezeshgi A. COVID-19 and kidney; a mini-review on current concepts and new data. J. Nephropharmacol. 10(1), e01, 2021. DOI: 10.34172/npj.2021.01
7. Cheng Y., Luo R., Wang K., Zhang M., Wang Z., Dong L., et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 97(5), 829–838, 2020. DOI: 10.1016/j.kint.2020.03.005
8. Jameel Z.I., Kadhim Z.K., Banoon S.R. Review about COVID-19. Res. J. Biotech. 16(4), 229-233, 2021.
9. Du Y., Tu L., Zhu P., Mu M., Wang R., Yang P., et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study. Am. J. Respir. Crit. Care Med. 201(11), 1372–1379, 2020. DOI: 10.1164/rccm.202003-0543OC
